Rasikrol Injection

Adult dosage

Add 20 mL of this medication to 1L of glucose nutritional solution or amino acid solution, and administer continuously through a central venous catheter for 24 hours at a rate of 83–125 mL per hour, totaling 2-3L per day. Phosphate can be added as potassium phosphate, corresponding to 10–30 mEq of potassium for 1L of non-oral nutrition solution. Contamination should be visually checked before infusion of the solution.

This medication may cause precipitation when mixed with ceftazidime in intravenous calcium-containing preparations, so it should not be administered simultaneously through the same infusion device. Allergic reactions may occur while using this medication; if symptoms of hypersensitivity appear, administration should be discontinued immediately, and appropriate treatment should be obtained. Since potassium is included, there is a risk of hyperkalemia, particularly in patients with impaired renal function or heart disease, who should be monitored closely for serum potassium levels. Due to the content of sodium and chloride, electrolyte imbalances such as hypernatremia, hyperchloremia, and metabolic acidosis may occur, so patients with related diseases or high-risk factors should have their serum sodium and chloride levels and renal function regularly monitored. This medication may cause hyponatremia, so special monitoring of symptoms and blood tests is required, particularly in young children, the elderly, post-operative patients, or those taking medications that increase the risk of hyponatremia. Due to the calcium content, there is a risk of hypercalcemia; therefore, it should be avoided in patients with hypercalcemia or a history of calcium kidney stones. Intravenous administration of this medication can cause fluid overload and electrolyte imbalance, so for patients at risk of fluid overload, fluid status and electrolyte concentrations should be checked periodically during administration. It should not be administered to patients with anuria, severe cardiovascular, renal, or hepatic impairment, in pediatric patients, or to patients with hypersensitivity to this medication or its components. Caution should be exercised in patients with congestive heart failure, severe renal insufficiency, hyperkalemia, metabolic alkalosis, severe liver dysfunction, or renal impairment; professional monitoring may be necessary if needed. Electrolyte concentrations such as sodium, potassium, and calcium may change with the use of this medication, so serum electrolyte levels should be frequently monitored for abnormalities. This medication may interact with other drugs, particularly ceftazidime, drugs that induce hyperkalemia, lithium, digoxin, and corticosteroids; monitoring of serum concentrations is necessary. The safety in pregnant women is unclear, so it should only be administered when the therapeutic benefits outweigh the risks. In pediatric patients, electrolyte regulation may be impaired, so serum electrolyte levels should be closely monitored, and rapid administration should be avoided, especially in low-birth-weight infants. Elderly patients may have decreased physiological functions, so care should be taken to administer the medication slowly and adjust dosages as necessary. If the solution is not clear or if the seal is broken, it should not be used, and as the solution is concentrated, it should be appropriately diluted before injection. Calcium and phosphate can precipitate each other; thus, when administering phosphates to patients requiring them, caution should be exercised, and potassium content should be combined with other medications for total potassium management.

Serious side effects

Urticaria, severe swelling (edema), chest tightness, difficulty breathing, chills, pallor, severe allergic reactions such as anaphylaxis, severe rashes with fever, blisters, severe skin reactions such as desquamation, difficulty or labored breathing, asthma attacks, respiratory complications associated with cough and fever, yellowing of the skin or eyes (jaundice), extreme lethargy, liver abnormalities, sudden

Mild side effects

• Hyperkalemia
• hypernatremia
• hyperchloremia
• hyponatremia
• hypercalcemia
• fluid overload
• electrolyte imbalance
• edema
• increased blood pressure
• muscle atrophy

This medication should be stored in a sealed container that prevents air and moisture access. The recommended storage temperature is between 1 and 30 degrees Celsius (room temperature). Proper storage will ensure the medication's efficacy is preserved.

Appearance

A colorless, transparent solution contained in a polypropylene container.

Package unit

20 milliliters x 50